|
1
|
Hezel AF and Zhu AX: Systemic therapy for
biliary tract cancers. Oncologist. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Limpaiboon T: Epigenetic aberrations in
cholangiocarcinoma: Potential biomarkers and promising target for
novel therapeutic strategies. Asian Pac J Cancer Prev. 13
Suppl:41–45. 2012.PubMed/NCBI
|
|
3
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marchion D and Münster P: Development of
histone deacetylase inhibitors for cancer treatment. Expert Rev
Anticancer Ther. 7:583–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu LN, Wang X and Zou SQ: Effect of
histone deacetylase inhibitor on proliferation of biliary tract
cancer cell lines. World J Gastroenterol. 14:2578–2581. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sriraksa R and Limpaiboon T: Histone
deacetylases and their inhibitors as potential therapeutic drugs
for cholangiocarcinoma-cell line findings. Asian Pac J Cancer Prev.
14:2503–2508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iwahashi S, Ishibashi H, Utsunomiya T,
Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S and
Shimada M: Effect of histone deacetylase inhibitor in combination
with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell
lines. J Med Invest. 58:106–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vleminckx K, Vakaet L Jr, Marreel M, Fiers
W and van Roy F: Genetic manipulation of E-cadherin expression by
epithelial tumor cells reveals an invasion suppressor role. Cell.
66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Fazio P, Montalbano R, Quint K, Alinger
B, Kemmerling R, Kiesslich T, Ocker M and Neureiter D: The
pan-deacetylase inhibitor panobinostat modulates the expression of
epithelial-mesenchymal markers in hepatocellular carcinoma models.
Oncol Lett. 5:127–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shah P, Gau Y and Sabnis G: Histone
deacetylase inhibitor entinostat reverses epithelial to mesenchymal
transition of breast cancer cells by reversing the repression of
E-cadherin. Breast Cancer Res Treat. 143:99–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Srivastava RK, Kurzrock R and Shankar S:
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits
angiogenesis and metastasis, and reverses epithelial-mesenchymal
transition in vivo. Mol Cancer Ther. 9:3254–3266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taylor MD, Liu Y, Nagji AS, Theodosakis N
and Jones DR: Combined proteasome and histone deacetylase
inhibition attenuates epithelial-mesenchymal transition through
E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg.
139:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng F, Sun G, Zhong M, Yu Y and Brewer
MA: Anticancer efficacy of cisplatin and trichostatin A or
5-aza-2′-deoxycytidine on ovarian cancer. Br J Cancer. 108:579–586.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaimori A, Potter JJ, Choti M, Ding Z,
Mezey E and Koteish AA: Histone deacetylase inhibition suppresses
the transforming growth factor beta1-induced
epithelial-to-mesenchymal transition in hepatocytes. Hepatology.
52:1033–1045. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao W, Chen X, Liu X, Luo L, Ye S and Liu
Y: Trichostatin A, a histone deacetylase inhibitor, suppresses
proliferation and epithelial-mesenchymal transition in retinal
pigment epithelium cells. J Cell Mol Med. 18:646–655. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen X, Xiao W, Chen W, Luo L, Ye S and
Liu Y: The epigenetic modifier trichostatin A, a histone
deacetylase inhibitor, suppresses proliferation and
epithelial-mesenchymal transition of lens epithelial cells. Cell
Death Dis. 4:e8842013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshikawa M, Hishikawa K, Marumo T and
Fujita T: Inhibition of histone deacetylase activity suppresses
epithelial-to-mesenchymal transition induced by TGF-beta1 in human
renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kong D, Ahmad A, Bao B, Li Y, Banerjee S
and Sarkar FH: Histone deacetylase inhibitors induce epithelial to
mesenchymal transition in prostate cancer cells. PLoS One.
7:e450452012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giudice FS, Pinto DS Jr, Nör JE, Squarize
CH and Castilho RM: Inhibition of histone deacetylase impacts
cancer stem cells and induces epithelial-mesenchyme transition of
head and neck cancer. PLoS One. 8:e586722013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang GM, Wang HS, Zhang F, Zhang KS, Liu
ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor
induction of epithelial-mesenchymal transitions via up-regulation
of Snail facilitates cancer progression. Biochim Biophys Acta.
1833:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ji M, Lee EJ, Kim KB, Kim Y, Sung R, Lee
SJ, Kim DS and Park SM: HDAC inhibitors induce
epithelial-mesenchymal transition in colon carcinoma cells. Oncol
Rep. 33:2299–2308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakamoto T, Kobayashi S, Yamada D, Nagano
H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, et
al: A histone deacetylase inhibitor suppresses
epithelial-mesenchymal transition and attenuates chemoresistance in
biliary tract cancer. PLoS One. 11:e01459852016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao X, Wang X, Dai L, Wang Z, Zhang G, Yan
Q and Zhou W: Clinicopathological and prognostic significance of
epithelial-mesenchymal transition related-protein in intrahepatic
cholangiocarcinoma. Onco Targets Ther. 5:255–261. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaquero J, Guedj N, Clapéron A, Nguyen
Ho-Bouldoires TH, Paradis V and Fouassier L: Epithelial-mesenchymal
transition in cholangiocarcinoma: From clinical evidence to
regulatory networks. J Hepatol. 66:424–441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY,
Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB and Park JG:
Establishment and characterisation of six human biliary tract
cancer cell lines. Br J Cancer. 87:187–193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sipos F and Galamb O:
Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions
in the colon. World J Gastroenterol. 18:601–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rittling SR and Baserga R: Functional
analysis and growth factor regulation of the human vimentin
promoter. Mol Cell Biol. 7:3908–3915. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lilienbaum A and Paulin D: Activation of
the human vimentin gene by the Tax human T-cell leukemia virus I:
Mechanisms of regulation by the NF-kappa B transcription factor. J
Biol Chem. 268:2180–2188. 1993.PubMed/NCBI
|
|
30
|
Chen JH, Vercamer C, Li Z, Paulin D,
Vandenbunder B and Stehelin D: PEA3 transactivates vimentin
promoter in mammary epithelial and tumor cells. Oncogene.
13:1667–1675. 1996.PubMed/NCBI
|
|
31
|
Salvetti A, Lilienbaum A, Li Z, Paulin D
and Gazzolo L: Identification of a negative element in the human
vimentin promoter: Modulation by the human T-cell leukemia virus
type I Tax protein. Mol Cell Biol. 13:89–97. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Y, Zhang X, Salmon M and Zehner ZE: The
Zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to
repress vimentin gene expression. Gene Cells. 12:905–918. 2007.
View Article : Google Scholar
|
|
33
|
Wang X, Xu J, Wag H, Wu L, Yuan W, Du J
and Cai S: Trichostatin A, a histone deacetylase inhibitor,
reverses epithelial-mesenchymal transition in colorectal cancer
SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun.
456:320–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han RF, Li K, Yang ZS, Chen ZG and Yang
WC: Trichostatin A induces mesenchymal-like morphological change
and gene expression but inhibits migration and colony formation in
human cancer cells. Mol Med Rep. 10:3211–3216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Techasen A, Loilome W, Namwat N, Khuntikeo
N, Puapairoj A, Jearanaikoon P, Saya H and Yongvanit P: Loss of
E-cadherin promotes migration and invasion of cholangiocarcinoma
cells and serves as a potential marker of metastasis. Tumor Biol.
35:8645–8652. 2014. View Article : Google Scholar
|
|
36
|
Xu W, Parmigiani R and Marks P: Histone
deacetylase inhibitors: Molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Donadelli M, Costanzo C, Beghelli S,
Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia
M, Scarpa A and Palmieri M: Synergistic inhibition of pancreatic
adenocarcinoma cell growth by trichostatin A and gemcitabine.
Biochim Biophys Acta. 1773:1095–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
